期刊
JOURNAL OF PHARMACEUTICAL ANALYSIS
卷 12, 期 4, 页码 556-569出版社
ELSEVIER
DOI: 10.1016/j.jpha.2022.04.001
关键词
Aggregation; Inhibitor; Therapeutic target; hIAPP; Type 2 diabetes mellitus
资金
- Wadhwani Research Foundation (Wadhwani Research Centre for Bioengineering) [BT/RLF/Re-entry/11/2012]
- Ramalingaswami Fellowship (Department of Biotechnology-DBT, Government of India) [BT/RLF/Re-entry/11/2012]
- (Department of Biotechnology-DBT, Government of India)
- University Grants Commission (Government of India) [F.4-5 (18-FRP) (IV-Cycle) /2017 (BSR)]
- (Government of India)
- Research and Development Grant
- Research and Development Grant
- CSIR-SRF, GOI
- [09/137/0602]
- [2019-EMR-I]
Type 2 diabetes mellitus and other metabolic disorders often go unnoticed due to the lack of suitable prognostic and diagnostic markers. The role of human islet amyloid polypeptide in regulating pancreatic β-cell function and inducing apoptosis is discussed in this review. Potential therapeutic approaches and drug targets for managing type 2 diabetes are explored.
Type 2 diabetes mellitus (T2DM) and other metabolic disorders are often silent and go unnoticed in patients because of the lack of suitable prognostic and diagnostic markers. The current therapeutic regimens available for managing T2DM do not reverse diabetes; instead, they delay the progression of diabetes. Their efficacy (in principle) may be significantly improved if implemented at earlier stages. The misfolding and aggregation of human islet amyloid polypeptide (hIAPP) or amylin has been associated with a gradual decrease in pancreatic b-cell function and mass in patients with T2DM. Hence, hIAPP has been recognized as a therapeutic target for managing T2DM. This review summarizes hIAPP's role in mediating dysfunction and apoptosis in pancreatic b-cells via induction of endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, inflammatory cytokine secretion, autophagy blockade, etc. Furthermore, it explores the possibility of using intermediates of the hIAPP aggregation pathway as potential drug targets for T2DM management. Finally, the effects of common antidiabetic molecules and repurposed drugs; other hIAPP mimetics and peptides; small organic molecules and natural compounds; nanoparticles, nanobodies, and quantum dots; metals and metal complexes; and chaperones that have demonstrated potential to inhibit and/or reverse hIAPP aggregation and can, therefore, be further developed for managing T2DM have been discussed. (C) 2022 The Author(s). Published by Elsevier B.V. on behalf of Xi'an Jiaotong University.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据